^
Association details:
| Biomarker: | MAP3K10 R304C |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Abstract 3365: MAP3K10 mutation as a biomarker for predicting response to chemotherapy in gastric cancer patients
Excerpt:
...we performed whole-exome sequencing (WES) on resistant tumor and paired normal samples from 14 patients received adjuvant chemotherapy. We found that 3 patients had novel somatic mutations...MAP3K10 R304C, MAP3K10 H211R, or MAP3K10 A30E were detected each patient, respectively....In summary, MAP3K10 R304C, MAP3K10 H211R, and MAP3K10 A30E confer resistance to cisplatin or 5-FU...
DOI:
10.1158/1538-7445.AM2018-3365
